Phase 2 Trial of Botensilimab + Balstilimab in Chemo-refractory Colorectal Cancer
A Phase 2 trial is investigating the efficacy and safety of botensilimab and balstilimab in patients with unresectable colorectal adenocarcinoma.
Asset / Drug
Drug and asset intelligence for botensilimab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Immunotherapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.